Aspergillus serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance
Journal of Clinical Microbiology · 08.07.2026 · 64 (7)
DOI: 10.1128/jcm.00182-26 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 08.07.2026. Verfasst von Jeanne Bigot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France. Hauptthemen laut MEDLINE: Pulmonary Aspergillosis, Antibodies, Fungal, Aspergillus, Blotting, Western. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic pulmonary aspergillosis (CPA) is a progressive and potentially fatal lung disease occurring in patients with underlying structural lung damage. Its diagnosis remains challenging because clinical and radiological features are often nonspecific and overlap with pre-existing respiratory conditions. Detection of anti- Aspergillus IgG antibodies is a cornerstone of diagnosis, as microscopy and culture have limited sensitivity. Several serological assays are available, including enzyme-linked immunosorbent assay (ELISA), which is highly sensitive but may lack specificity, and Western blot (WB), for which diagnostic performance data are limited. This study aimed to optimize the serological strategy for CPA diagnosis. The diagnostic performance of a commercial ELISA assay for Aspergillus -specific IgG (Platelia Aspergillus IgG, Bio-Rad) was optimized using serum samples collected at diagnosis from CPA patients and control subjects. Receiver operating characteristic (ROC) curve analysis was performed to assess alternative cut-off values. In parallel, the performance of a commercial WB assay (LDBio) was retrospectively evaluated using serum samples from five groups: CPA, Aspergillus colonization, airway contamination, negative controls with chronic respiratory disease, and healthy donors. ROC curve analysis showed that increasing the ELISA cut-off from 10 to 25 AU/mL maintained excellent sensitivity while improving specificity from 83.5% to 92.8%. The WB assay demonstrated a sensitivity of 87.0% for CPA diagnosis; however, specificity varied depending on the control group, ranging from 41.4% to 60.7%. Adjusting the ELISA threshold to 25 AU/mL significantly enhances diagnostic specificity without compromising sensitivity, whereas WB provides limited additional diagnostic value due to suboptimal specificity. IMPORTANCE Chronic pulmonary aspergillosis (CPA) is a severe and often overlooked fungal lung disease that occurs in patients with underlying structural pulmonary disorders. Diagnosis is challenging because clinical and radiological features are frequently nonspecific and overlap with pre-existing lung conditions. Detection of anti- Aspergillus IgG is central to diagnosis, but the optimal interpretation of available assays remains uncertain. In this study, we assessed the diagnostic performance of serological tests using well-defined patient groups reflecting real-world clinical practice. We show that increasing the cut-off of a widely used ELISA assay significantly improves diagnostic specificity without compromising sensitivity. In contrast, our results suggest that a commercial Western blot test provides only limited diagnostic value due to suboptimal specificity, clearly demonstrated using the different patient groups studied. These results help refine the serological strategy for CPA diagnosis and improve its clinical interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.
- GRC40 SoLID, SOrbonne study group for Lung Infectious Diseases, Sorbonne Université, Paris, France.
- Service de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Antoine et Sorbonne Université, Paris, France.
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France.
- Service de Pneumologie et d'Oncologie Thoracique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon et Sorbonne Université, Paris, France.
- Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), Paris, France.
ORCID-Profile: Jeanne Bigot, Charles Gibert, Juliette Guitard
Zitieren
APA
Bigot, J., Gibert, C., Millet, N., Abderrahim, W., Thorez, S., Senghor, Y., Cadranel, J., Godet, C., Hennequin, C., Maitre, T., & Guitard, J. (2026). Aspergillus serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance. Journal of Clinical Microbiology, 64(7). https://doi.org/10.1128/jcm.00182-26
Vancouver
Bigot J, Gibert C, Millet N, Abderrahim W, Thorez S, Senghor Y, et al. Aspergillus serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance. Journal of Clinical Microbiology. 2026;64(7). doi:10.1128/jcm.00182-26
BibTeX
@article{Bigot2026,
author = {Bigot, Jeanne and Gibert, Charles and Millet, Nicolas and Abderrahim, Wissem and Thorez, Sophie and Senghor, Yaye and Cadranel, Jacques and Godet, Cendrine and Hennequin, Christophe and Maitre, Thomas and Guitard, Juliette},
title = {Aspergillus serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {7},
doi = {10.1128/jcm.00182-26}
}
EUVIMED